United States: Nicox To Acquire Aciex Therapeutics, Inc.
Last Updated: July 9 2014

Nicox S.A. today announced it has signed an agreement to acquire all of the outstanding equity of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation. The completion of the acquisition remains subject to the approval of Nicox's shareholders and other customary conditions.

WilmerHale is representing Aciex Therapeutics in this deal, with a team being led by Partner Josh Fox that includes Partners A. William Caporizzo, Jeff Hermanson and Belinda Juran, a well as Senior Associates Livingston Miller and Meghan Walsh, and Associate Colin Beavais.

The formal press release with full details of the transaction can be found on Nicox's site.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Raya Treiser, Rob Lehman
By Gary Born
By Leila Gaafar
By Timothy Silva, Seth Davis
By Christopher Babbitt, Jonathan Bressler, Claire Chung
By WilmerHale
By Jonathan Yarowsky, Perry A. Lange, Hartmut Schneider, Leon Greenfield, D. Reed Freeman, Jr., Heather Zachary
By Jay Holtmeier, Erin Sloane
By Geoffroy Barthet, Nicole Callan, Cormac O'Daly, Hartmut Schneider
By WilmerHale
Tools
Print
Font Size:
Translation
Channels